By Samuel Okafor, BSN, RN, Registered Nurse, Endocrinology. Medically reviewed by Dr. Hassan Karimi, MD, Board-Certified Endocrinology.
This guide assumes you're past the basics. If you're still in your first week of GLP-1 therapy, the beginner resources will serve you better. Here, we're getting into the edge cases, the dosing arithmetic, and the questions that actually come up in clinical follow-ups.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Diet & Food hub.
The Short Answer, Then the Interesting Part
Mariana, a 38-year-old paralegal in Houston, was six weeks into compounded tirzepatide at 5 mg when she texted her telehealth provider at 11 p.m. on a Tuesday: "I have zero appetite for dinner most nights, but I'd murder someone for a block of sharp cheddar. Is something wrong with me?" Her provider told her what endocrinology nurses hear constantly: cheese cravings on GLP-1 therapy are common, and they aren't random.
Here's the thing. About 720 people a month type "why am I craving cheese" into Google. A good chunk of them, based on the query patterns, are on appetite-suppressing medications. When your overall hunger drops but one specific craving persists (or even intensifies), it feels like your body is sending a telegram. And in a sense, it is.
Cheese is a near-perfect storm of caloric density, fat, salt, and casomorphins, opioid-like peptides produced during casein digestion. Your brain's reward circuitry treats cheese differently than it treats, say, steamed broccoli. GLP-1 agonists dampen generalized appetite signals through the hypothalamus, but they don't uniformly erase hedonic (pleasure-driven) food motivation. Think of it like noise-canceling headphones that block background hum but still let a siren through. Cheese is the siren.
That said, craving cheese isn't necessarily a problem to solve. It's calorie-dense, yes. But it's also a legitimate source of protein, calcium, and fat, all of which matter more, not less, when your total intake is reduced on GLP-1 therapy.
What GLP-1 Agonists Actually Do to Appetite Circuits
GLP-1 receptor agonists mimic the incretin hormone GLP-1. They slow gastric emptying, suppress glucagon release, enhance glucose-dependent insulin secretion, and act on central appetite-regulating circuits in the brainstem and hypothalamus. The net effect: most people eat less, feel full sooner, and spend less time thinking about food.
Tirzepatide adds a second mechanism, GIP receptor agonism. Pre-clinical work suggests the GIP pathway may complement GLP-1 by improving GI tolerability ceilings and affecting adipose-tissue physiology in ways we're still mapping.
But "less hunger" and "no cravings" are not the same thing. Homeostatic hunger (your body needing calories) and hedonic drive (your brain wanting pleasure from food) run on overlapping but distinct pathways. GLP-1 therapy is better at suppressing the first than the second. Cheese, chocolate, and salty snacks tend to persist as cravings precisely because they're tied to dopamine reward loops, not just caloric need.
So if you're on tirzepatide and find yourself indifferent to most meals but fixated on a wedge of Gruyère, you're not broken. You're experiencing the pharmacology doing exactly what it does.
The Nutritional Calculus on Reduced Intake
This is where cheese cravings get genuinely interesting from a clinical standpoint. When total caloric intake drops (which it does for most patients on GLP-1 therapy), every bite carries more nutritional weight. Protein is the macronutrient most likely to fall short, and inadequate protein intake during pharmacologic weight loss accelerates lean mass loss.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →An ounce of cheddar delivers about 7 grams of protein and 9 grams of fat. That's not nothing. A couple of ounces of cheese as a snack, paired with some fruit or a handful of nuts, is a reasonable calorie package for someone eating 1,200 to 1,500 calories a day. The boring truth is that moderate cheese consumption on GLP-1 therapy is fine for most people, and sometimes it's actively useful for hitting protein targets.
Where this falls apart is portion size. One ounce of cheese is roughly the size of four dice. Most people, left to their own devices with a block of aged Gouda and a knife, will eat three to four times that before they register what happened. On a reduced-calorie day, that's a significant chunk of your budget going to a single sitting.
Lifestyle interventions (protein-forward eating, resistance training, hydration, sleep) amplify GLP-1-mediated weight loss. SURMOUNT-3 explicitly examined this combination. The takeaway: cheese isn't the enemy, but the full dietary pattern matters more than any single food.
Dosing Math You Should Actually Understand
A quick detour that's relevant here, because many people reading this are on compounded GLP-1 products and managing their own injections.
Dosing math for compounded products comes down to two numbers: vial concentration and prescribed dose in milligrams. Volume to draw equals the prescribed dose divided by the concentration. Units on a U-100 syringe equals volume in mL multiplied by 100.
Example 1. Vial concentration: 10 mg/mL. Prescribed dose: 2.5 mg. Volume: 2.5 ÷ 10 = 0.25 mL. On a U-100 syringe, draw to the 25-unit mark.
Example 2. Vial concentration: 5 mg/mL. Same 2.5 mg dose. Volume: 2.5 ÷ 5 = 0.5 mL. Draw to the 50-unit mark.
The arithmetic is simple. The error that actually causes problems is forgetting to re-check concentration when the pharmacy ships a different lot or fill volume. The unit number that worked last month may correspond to a different milligram dose this month if the concentration changed. Read the label every single fill.
What the Trials Show (and What They Don't)
STEP 5 (Garvey et al., Nat Med 2022) extended semaglutide 2.4 mg evaluation to 104 weeks. SELECT (Lincoff et al., NEJM 2023) studied cardiovascular outcomes of semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity. LEADER (Marso et al., NEJM 2016) evaluated cardiovascular outcomes of liraglutide in type 2 diabetes.
None of these trials measured cheese cravings. (I know. Disappointing.) But they do establish the pharmacodynamic context: these drugs produce meaningful, sustained weight loss with wide individual variance around the mean. Some people lose 20%+ of body weight; others lose 5%. Trial averages are averages, full stop.
What we can extract: cravings for calorie-dense, high-palatability foods are well-documented during appetite suppression therapy. They're not a sign the medication isn't working. They're a sign your reward system is negotiating with your pharmacology.
SURMOUNT-1 and STEP 1 show continued gradual weight loss through their 68-to-72-week windows, with most of the absolute change occurring in the first half. Plateaus are normal. They do not mean the drug has "stopped working."
Protocol Adjustments and When to Flag a Craving
Adherence and persistence are the largest real-world variables in GLP-1 outcomes. Patients who stay on therapy for 12 months maintain meaningfully larger losses than those who discontinue within 90 days.
The clinical tools at a routine follow-up include: hold at current dose, advance to the next step, drop back, extend the interval between injections by a day or two, or temporarily pause and resume lower. Roughly half of patients in real-world cohorts experience side effects significant enough to warrant a temporary pause or slower escalation at some point in the first six months. This is anticipated, not alarming.
So when is a cheese craving worth mentioning to your prescriber? When it's a proxy for something else. If you're craving cheese because you're eating 800 calories a day and your body is screaming for fat and protein, that's a nutrition problem, not a willpower problem. If cheese is the only thing that sounds good and you're skipping meals entirely, that's a conversation about whether the dose is too aggressive.
My genuinely opinionated take: too many patients on GLP-1 therapy treat any food desire as a moral failure. A craving for cheese is your body requesting fat, salt, calcium, and pleasure. Three of those four are legitimate physiological needs. The fourth (pleasure) isn't illegitimate either. The question is always proportion, not permission.
Misconceptions Worth Clearing Up
"More drug, less craving." Not how it works. Above the trial-validated dose range, additional medication does not proportionally increase efficacy and often worsens tolerability. The escalation schedule reflects published trial design, not arbitrary caution.
"Side effects mean it's working." Side effects correlate with dose escalation and individual sensitivity, not with weight-loss magnitude. People with minimal GI symptoms can lose significant weight. People with terrible nausea don't necessarily lose more.
"If I crave it, my body needs it." Sometimes. Cravings for protein-rich or mineral-rich foods during caloric restriction often do reflect genuine nutritional shortfalls. But the "intuitive eating" framework breaks down with hyper-palatable foods engineered to trigger overconsumption. Cheese lives in a gray zone: it has real nutritional value AND it activates reward pathways disproportionately. Treat the craving as information, not as a command.
Special Populations and Contraindications
Special-population considerations include severe renal or hepatic impairment, history of pancreatitis, personal or family history of medullary thyroid carcinoma or MEN2 syndrome (a contraindication for GLP-1 receptor agonists), severe gastroparesis, and active gallbladder disease. Each affects the risk-benefit calculation and may change the protocol entirely.
Pregnancy and breastfeeding are not appropriate windows for GLP-1 therapy. Patients planning pregnancy are typically advised to discontinue at least two months before attempting to conceive.
Patients on insulin or insulin secretagogues require dose adjustments to those medications when GLP-1 therapy is added, to reduce hypoglycemia risk. This is a prescriber-led decision.
Related reading
- How to keep bread fresh?
- Does drinking lemon water help lose weight?
- Does drinking tea help lose weight?
- Evaluating Compounded GLP-1 Telehealth Programs: A Buyer Framework (Practical)
- Does tirzepatide stop working?
Frequently Asked Questions
Is this something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. This article is general education, not a substitute for individualized guidance.
Where does cheese fit into my overall GLP-1 plan?
Most dietary decisions on GLP-1 therapy make more sense in context: your indication, comorbidities, protein targets, and caloric floor. A prescriber or registered dietitian can help you figure out whether cheese is filling a nutritional gap or blowing your calorie budget.
What if my cravings feel more extreme than what's described here?
Extreme or obsessive food fixation on any appetite-suppressing medication warrants a longer conversation with your provider. It may indicate the dose needs adjustment, caloric intake is too low, or there's an underlying relationship with food that benefits from specialized support.
How often will the guidance here change?
The underlying mechanisms and foundational trial data are stable. Coverage, pricing, and regulatory specifics shift more often. Confirm anything time-sensitive with a current source.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
Can cheese cravings indicate a calcium deficiency?
Possibly, though the evidence for craving-as-deficiency-signal is weaker than popular culture suggests. If you suspect a deficiency, bloodwork is more reliable than craving interpretation. That said, ensuring adequate calcium intake on a reduced-calorie diet is clinically sensible regardless of what your cravings are telling you.
Should I switch to lower-fat cheese to manage calories?
It depends on your goals and your total intake. Reduced-fat cheese has fewer calories per ounce but often less satiety. Full-fat cheese in smaller portions may keep you satisfied longer. There's no universal right answer here.
Continue the Series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About This Article
Written by Samuel Okafor, BSN, RN (Registered Nurse, Endocrinology). Medically reviewed by Dr. Hassan Karimi, MD (Board-Certified Endocrinology). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.